Cizzle Biotechnology Shortlisted for Best Non-Therapeutic R&D Company at One Nucleus Awards 2026

Cizzle Biotechnology Holdings plc has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Awards 2026, the UK diagnostics developer of early cancer tests said on October 19, 2026. The shortlisting was announced by Investegate.

Cizzle's One Nucleus Shortlisting and Genesis Invitation

Cizzle Biotechnology is a UK-based developer of early cancer tests, built around the CIZ1B biomarker, a naturally occurring variant of the cell nuclear protein CIZ1 that is highly associated with early-stage lung cancer and can be measured in small quantities of blood. The company has developed CIZ1B into a non-invasive, cost-effective blood test for the early detection of lung cancer.

Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We are delighted that Cizzle has been shortlisted for Best Non-Therapeutic R&D Company of the Year. Having spent many years developing our CIZ1B technology, this recognition comes at an important point as we progress the commercialisation of our lung cancer biomarker test."

The Best Non-Therapeutic R&D Company of the Year category applies to companies undertaking research and development of new health technologies, including diagnostics, patient stratification, drug delivery and digital health. Finalists are selected by an expert panel of biotechnology experts and journalists from leading publications, and candidates are assessed against published criteria covering innovation, potential impact on patient outcomes, financing and deals, leadership, and environmental, social and governance considerations.

Cizzle has also been invited to present at the Genesis conference to an audience specifically looking for collaboration and new deal flows. The awards are presented by One Nucleus, a not-for-profit life sciences and healthcare membership organisation headquartered in Cambridge, as part of its flagship Genesis Conference. This year's conference, themed "Maximising Returns from Life Science Innovation", is expected to attract more than 400 delegates.

The CIZ1B biomarker test is built on foundational research into cancer origins and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. In June 2026, the test was successfully accredited for use in the United States under the Clinical Laboratory Improvement Amendments (CLIA) at OmniHealth Diagnostics, providing a regulated laboratory route to market that enables licensed US healthcare providers to order the test. Cizzle's licensing partner Cizzle Bio is now promoting the test to clinicians and patients, and Cizzle is working with potential partners to bring the test to commercial and NHS laboratories in the UK and Europe. Cizzle was admitted to the Official List and Main Market of the London Stock Exchange in May 2021.

Cizzle's US Rollout and Partner Deals

In July 2026, Cizzle Biotechnology launched its CIZ1B Biomarker Blood Test for lung cancer in Texas, the first phase of its US commercialization, according to Pharmafile. The ELISA-based test detects the CIZ1B biomarker, with validation at OmniHealth Diagnostics and plans for additional CLIA-certified partners.

In August 2026, Cizzle Biotechnology Holdings plc announced that its North American licensing partner, Cizzle Bio Inc, had signed a laboratory agreement with BioBridge Global, making BBG Advanced Therapies a CLIA-certified partner to offer the CIZ1B Biomarker Blood Test for Lung Cancer across South Texas, Investing.com reported.

Cizzle's December Genesis Presentation

Cizzle will present its CIZ1B lung cancer biomarker test at the Genesis conference in December 2026, the company said. The company's own announcement is available at cizzlebiotechnology.com.